Biogen to pay $700M to boost stake in Samsung biologics joint venture

The joint venture, called Samsung Bioepis, has gotten a handful of biosimilar drugs approved in Europe, the U.S. and various foreign nations since being founded six years ago.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.